NCT04361032View on ClinicalTrials.gov

Assessment of Efficacy and Safety of Tocilizumab Compared to DefeROxamine, Associated With Standards Treatments in COVID-19 (+) Patients Hospitalized In Intensive Care in Tunisia

PHASE3UnknownINTERVENTIONAL
Enrollment

260

Participants

Timeline

Start Date

September 4, 2020

Primary Completion Date

September 4, 2020

Study Completion Date

October 4, 2020

Conditions
COVID19Intensive Care Unit
Interventions
DRUG

Tocilizumab Injection

Tocilizumab (LOC) (8mg/ kg per day) (1 injection per infusion). Only on the 1st day (D0)

DRUG

Deferoxamine

Deferoxamine (Desferal 500 mg, powder, and solvent for IV solution for injection)

Trial Locations (1)

Unknown

Eshmoun Clinical Research Centre/ Hôpital Abderrahmane Mami-Ariana, Aryanah

Sponsors
All Listed Sponsors
collaborator

Eshmoun Clinical Research Center

NETWORK

collaborator

Datametrix

INDUSTRY

lead

Abderrahmane Mami Hospital

OTHER